Eli Lilly and Company: Psychotic Disorders trials
The registry lists 10 Psychotic Disorders studies with Eli Lilly and Company as lead sponsor. 0 are open to participants now and 5 have results posted.
Phase 1 1Phase 3 2Phase 4 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With OlanzapineCompletedNCT00401973Phase 3Results posted
- Efficacy Study of Early Onset of Antipsychotic Drug Action in SchizophreniaCompletedNCT00337662Phase 4Results posted
- Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)CompletedNCT00303602Phase 4Results posted
- Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective DisorderCompletedNCT00190749Phase 4Results posted
- Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT00088465Phase 3Results posted
- Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective DisorderCompletedNCT00100776Phase 4
- Pharmacokinetic Characterization of Intramuscular Olanzapine DepotCompletedNCT00094640Phase 1
- Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective DisorderCompletedNCT00090012Phase 4
- The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I DisorderCompletedNCT00044187Phase 4
- Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With SchizophreniaCompletedNCT00034801Phase 4